Literature DB >> 18079321

Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.

Leah S Lyons1, Shuyun Rao, Wayne Balkan, Joanne Faysal, Carol A Maiorino, Kerry L Burnstein.   

Abstract

Prostate cancer invariably recurs after androgen deprivation therapy. Growth of this recurrent/androgen-independent form of prostate cancer may be due to increased androgen receptor (AR) transcriptional activity in the absence of androgen. This ligand-independent AR activation is promoted by some growth factors but the mechanism is not well understood. Vav3, a Rho guanosine triphosphatase guanine nucleotide exchange factor, which is activated by growth factors, is up-regulated in human prostate cancer. We show here that Vav3 levels increase during in vivo progression of prostate cancer to androgen independence. Vav3 strikingly enhanced growth factor activation of AR in the absence of androgen. Because Vav3 may be chronically activated in prostate cancer by growth factor receptors, we examined the effects of a constitutively active (Ca) form of Vav3 on AR transcriptional activity. Ca Vav3 caused nuclear localization and ligand-independent activation of AR via the Rho guanosine triphosphatase, Rac1. Ca Rac1 activation of AR occurred, in part, through MAPK/ERK signaling. Expression of active Rac1 conferred androgen-independent growth of prostate cancer cells in culture, soft agar, and mice. These findings suggest that Vav3/Rac 1 signaling is an important modulator of ligand-independent AR transcriptional activity in prostate cancer progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079321      PMCID: PMC2262175          DOI: 10.1210/me.2007-0158

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  58 in total

1.  Structural determinants for the biological activity of Vav proteins.

Authors:  José L Zugaza; Miguel A López-Lago; María J Caloca; Mercedes Dosil; Nieves Movilla; Xosé R Bustelo
Journal:  J Biol Chem       Date:  2002-09-12       Impact factor: 5.157

2.  Rho family Guanine nucleotide exchange factor Brx couples extracellular signals to the glucocorticoid signaling system.

Authors:  Tomoshige Kino; Emanuel Souvatzoglou; Evangelia Charmandari; Takamasa Ichijo; Paul Driggers; Chantal Mayers; Anton Alatsatianos; Irini Manoli; Heiner Westphal; George P Chrousos; James H Segars
Journal:  J Biol Chem       Date:  2006-02-08       Impact factor: 5.157

3.  Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.

Authors:  Scott M Dehm; Donald J Tindall
Journal:  J Biol Chem       Date:  2006-07-25       Impact factor: 5.157

4.  Regulation of androgen receptor activity by tyrosine phosphorylation.

Authors:  Zhiyong Guo; Bojie Dai; Tianyun Jiang; Kexin Xu; Yingqiu Xie; Oekyung Kim; Issa Nesheiwat; Xiangtian Kong; Jonathan Melamed; Venkatesh D Handratta; Vincent C O Njar; Angela M H Brodie; Li-Rong Yu; Timothy D Veenstra; Hegang Chen; Yun Qiu
Journal:  Cancer Cell       Date:  2006-10       Impact factor: 31.743

5.  Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.

Authors:  Zhongyun Dong; Yin Liu; Shan Lu; Amy Wang; Kiwon Lee; Lu-Hai Wang; Monica Revelo; Shan Lu
Journal:  Mol Endocrinol       Date:  2006-06-08

6.  Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.

Authors:  Yan Xie; Dennis W Wolff; Ming-Fong Lin; Yaping Tu
Journal:  Mol Pharmacol       Date:  2007-04-12       Impact factor: 4.436

7.  Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.

Authors:  Leah S Lyons; Kerry L Burnstein
Journal:  Mol Endocrinol       Date:  2005-12-29

8.  Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.

Authors:  Petra Hååg; Jasmin Bektic; Georg Bartsch; Helmut Klocker; Iris E Eder
Journal:  J Steroid Biochem Mol Biol       Date:  2005-08       Impact factor: 4.292

Review 9.  Androgen receptor cross-talk with cell signalling pathways.

Authors:  Zoran Culig
Journal:  Growth Factors       Date:  2004-09       Impact factor: 2.511

10.  Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.

Authors:  Helen Cheng; Rob Snoek; Fariba Ghaidi; Michael E Cox; Paul S Rennie
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

View more
  30 in total

Review 1.  Androgen Receptor Structure, Function and Biology: From Bench to Bedside.

Authors:  Rachel A Davey; Mathis Grossmann
Journal:  Clin Biochem Rev       Date:  2016-02

2.  Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity.

Authors:  Sarvesh Jajoo; Debashree Mukherjea; Kounosuke Watabe; Vickram Ramkumar
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

Review 3.  Minireview: Tipping the balance: ligand-independent activation of steroid receptors.

Authors:  Marcela A Bennesch; Didier Picard
Journal:  Mol Endocrinol       Date:  2015-01-27

4.  Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Authors:  Stephanie O Peacock; Cale D Fahrenholtz; Kerry L Burnstein
Journal:  Mol Endocrinol       Date:  2012-09-28

Review 5.  Androgen deprivation and immunotherapy for the treatment of prostate cancer.

Authors:  Melissa Gamat; Douglas G McNeel
Journal:  Endocr Relat Cancer       Date:  2017-08-16       Impact factor: 5.678

6.  Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.

Authors:  Fiorella Magani; Stephanie O Peacock; Meghan A Rice; Maria J Martinez; Ann M Greene; Pablo S Magani; Rolando Lyles; Jonathan R Weitz; Kerry L Burnstein
Journal:  Mol Cancer Res       Date:  2017-08-15       Impact factor: 5.852

Review 7.  Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.

Authors:  Miki Nagase; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2013-01-08       Impact factor: 28.314

8.  Inhibition of Vav3 gene can promote apoptosis of human gastric cancer cell line MGC803 by regulating ERK pathway.

Authors:  Bi-Bo Tan; Ming-Ming Zhang; Yong Li; Qun Zhao; Li-Qiao Fan; Yu Liu; Dong Wang
Journal:  Tumour Biol       Date:  2015-12-22

Review 9.  The role of microRNA in castration-resistant prostate cancer.

Authors:  William Thieu; Derya Tilki; Ralph de Vere White; Christopher P Evans
Journal:  Urol Oncol       Date:  2014-07       Impact factor: 3.498

10.  Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.

Authors:  Fayi Wu; Stephanie O Peacock; Shuyun Rao; Sandra K Lemmon; Kerry L Burnstein
Journal:  J Biol Chem       Date:  2012-12-31       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.